THE USE OF TOFACITINIB FOR TREATMENT PATIENTS WITH PSORIASIS IN CONDITIONS OF THE DERMATOLOGICAL HOSPITAL

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract


A growing understanding of the cellular and molecular mechanisms of inflammation in psoriasis and psoriatic arthritis opens the way to the treatment these diseases with the help of new small molecules, associated with the blockade of intracellular signal transduction. Jaqinus®/Xeljanz® (tofacitinib, “Pfizer”) is the first oral inhibitor of Janus kinases for the treatment of chronic moderately severe and severe plaque psoriasiswhich was approved for usage in Russia. The authors also present own local data regarding usage of tofacitinib 10 and 20 mg/day by short course for the treatment group of 13 patients with severe forms of plaque psoriasis in a progressing stage with resistance to prior systemic conventional therapy who were treated at the TDVCD. The efficacy of therapeutic strategies with the use of tofacitinib for patients of the dermatological hospital with the aim of improving and stabilizing of acute process is shown. Further prospective and observational studies to refine the dosing and safety profile of this group of drugs are needed.

Full Text

Restricted Access

About the authors

Ella V. Natarova

Tula Regional Clinical Dermatovenerologic Dispensary

Email: natarova_ella@list.ru
Tula, 300052, Russian Federation
Deputy chief physician on medical part, doctor of the highest qualification category, Dermatovenerologic Clinical Dispensary of Tula, Tula, 300052, Russian Federation.

N. S Rudneva

Tula Regional Clinical Dermatovenerologic Dispensary

Tula, 300052, Russian Federation

M. S Kuklina

Tula Regional Clinical Dermatovenerologic Dispensary

Tula, 300052, Russian Federation

Ya. Yu Chumakova

Tula Regional Clinical Dermatovenerologic Dispensary

Tula, 300052, Russian Federation

References

  1. Mansouri Y., Goldenberg G. New systemic therapies for psoriasis. Cutis. 2015; 95(3): 155-60. http://www.ncbi.nlm.nih.gov/pubmed/25844781
  2. Helmick C.G., Lee-Han H., Hirsch S.C., Baird T.L., Bartlett C.L. Prevalence of psoriasis among adults in the U.S.: 2003-2006 and 2009-2010 National Health and Nutrition Examination Surveys. Am. J. Prev. Med. 2014; 47(1): 37-45. doi: 10.1016/j.amepre.2014.02.012.
  3. Lopez-Estebaranz J.L., Sanchez-Carazo J.L., Sulleiro S. Effect of a family history of psoriasis and age on comorbidities and quality of life in patients with moderate to severe psoriasis: results from the ARIZONA study. J. Dermatol. 2016; 43(4): 395-401. doi: 10.1111/1346-8138.13157.
  4. Korman A.M., Hill D., Alikhan A., Feldman S.R. Impact and management of depression in psoriasis patients. Expert Opin. Pharmacother. 2016; 17(2): 147-52. doi: 10.1517/14656566.2016.1128894.
  5. Ritchlina C.T., Kruegerb J.G. New therapies for psoriasis and psoriatic arthritis. Curr. Opin. Rheumatol. 2016, 28(3): 204-10.
  6. Murphy M., Kerr P., Grant-Kels J.M. Thehistopathologic spectrum of psoriasis. Clin. Dermatol. 2007; 25(6): 524-8.
  7. Lowes M.A., Suarez-Farinas M., Krueger J.G. Immunology of psoriasis. Annu. Rev. Immunol. 2014; 32: 227-55.
  8. Zaba L.C., Krueger J.G., Lowes M.A. Resident and “inflammatory”dendritic cells in human skin. J. Invest. Dermatol. 2009; 129(2): 302-8. doi: 10.1038/jid.2008.225.
  9. American Academy of Dermatology Work Group, Menter A., Korman N.J., Elmets C.A., Feldman S.R., Gelfand J.M., Gordon K.B., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J. Am. Acad. Dermatol. 2011; 65(1): 137-74. doi: 10.1016/j.jaad.2010.11.055.
  10. Puig L. PASI 90 response: the new standard in therapeutic efficacy for psoriasis. J. Eur. Acad. Dermatol. Venereol. 2015; 29(4): 645-8. doi: 10.1111/jdv.12817.
  11. Олисова О.Ю. Современные подходы к ведению больных псориазом. Русский медицинский журнал. 2004; 12(4): 182-5
  12. Pathirana D., Ormerod A.D., Saiag P., Smith C., Spuls P.I., Nast A., et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J. Eur. Acad. Dermatol. Venereol. 2009; 23(Suppl. 2): 1-70.
  13. Naldi L., Griffiths C.E. Traditional therapiesin the management of moderate to severechronic plaque psoriasis: an assessment of the benefits and risks. Br. J. Dermatol. 2005; 152(4): 597-615.
  14. Carretero G., Ferrandiz C., Dauden E., Vanaclocha Sebastian F., Gomez-Garcia F.J., Herrera-Ceballos E., et al.; BIOBADADERM Study Group. Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry. J. Eur. Acad. Dermatol. Venereol. 2015; 29(1): 156-63. doi: 10.1111/jdv.12492.
  15. Christophers E., Segaert S., Milligan G., Molta C.T., Boggs R. Clinical improvement and satisfaction with biologic therapy in patients with severe plaque psoriasis: results of a European cross-sectional observational study. J. Dermatol. Treat. 2013; 24(3): 193-8. doi: 10.3109/09546634.2012.697112.
  16. Hsu S., Papp K.A., Lebwohl M.G., Bagel J., Blauvelt A., Duffin K.C., et al.; National Psoriasis Foundation Medical Board. Consensus guidelines for the managementof plaque psoriasis. Arch. Dermatol. 2012; 148(1): 95-102.
  17. Gaspari A.A., Tyring S. New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors. Dermatol. Ther. 2015; 28(4): 179-93. doi: 10.1111/dth.12251
  18. Brunasso A.M., Puntoni M., Salvini C., Delfino C., Curcic P., Gulia A., Massone C. Tolerability and safety of biological therapies for psoriasis in daily clinical practice: a study of 103 Italian patients. Acta Derm. Venereol. 2011; 91(1): 44-9. doi: 10.2340/00015555-0959.
  19. Jacobs A., Rosumeck S., Nast A. Systematic review on the maintenance of response during systemic antipsoriatic therapy. Br. J. Dermatol. 2015; 173(4): 910-21.
  20. Gniadecki R., Kragballe K., Dam T.N., Skov L. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br. J. Dermatol. 2011; 164(5): 1091-6. doi: 10.1111/j.1365-2133.2011.10213.x.
  21. Yeung H., Wan J., Van Voorhees A.S., Callis Duffin K., Krueger G.G., Kalb R.E., et al. Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. J. Am. Acad. Dermatol. 2013; 68(1): 64-72. doi: 10.1016/j.jaad.2012.06.035.
  22. Levin A.A., Gottlieb A.B., Au S.C. A comparison of psoriasis drug failure rates and reasons for discontinuation in biologics vs conventional systemic therapies. J. Drugs. Dermatol. 2014; 13(7): 848-53. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25007369
  23. Hansen R.B., Kavanaugh A. Novel treatments with small molecules in psoriatic arthritis. Curr. Rheumatol. Rep. 2014; 16(9): 443.
  24. Kofoed K., Skov L., Zachariae C. New drugs and treatment targets in psoriasis. Acta Derm. Venereol. 2015; 95(2): 133-9.
  25. Torres T., Filipe P. Small molecules in the treatment of psoriasis. Drug. Dev. Res. 2015; 76(5): 215-27. doi: 10.1002/ddr.21263
  26. Bachelez H., van de Kerkhof P.C., Strohal R., Kubanov A., Valenzuela F., Lee J.H.,; OPT Compare Investigators. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet. 2015; 386(9993): 552-61.
  27. Shreberk-Hassidim R., Ramot Y., Zlotogorski A. Janus kinase inhibitors in dermatology: A systematic review. J. Am. Acad. Dermatol. 2017; 76(4): 745-53.e19. doi: 10.1016/j.jaad.2016.12.004. Available at: http://dx.doi.org/10.1016/j.jaad.2016.12.004
  28. Регистрационное удостоверение лекарственного препарата Яквинус для медицинского применения ЛП-002026.
  29. Инструкция по медицинскому применению препарата Яквинус - таблетки, покрытые пленочной оболочкой, утверждена Минздравом РФ 16.03.13, рег. уд. ЛП 002026-190913 от 16.03.13 с изменениями от 08.10.15.
  30. Palanivel J.A., Macbeth A.E., Chetty N.C., Levell N.J. An insight into JAK-STAT signalling in dermatology. Clin. Exp. Dermatol. 2014; 39(4): 513-8. doi: 10.1111/ced.12273.
  31. Ghoreschi K., Gadina M. Jakpot! New small molecules in autoimmune and inflammatory diseases. Exp. Dermatol. 2014; 23(1): 7-11. doi: 10.1111/exd.12265.
  32. Клинические рекомендации «Псориаз» МКБ-10: L40. Возрастная категория: взрослые, дети, ID: КР234; 2016. Available at: http://cr.rosminzdrav.ru/schema.html?id=866#/text
  33. Papp K.A., Menter M.A., Abe M., Elewski B., Feldman S.R., Gottlieb A.B., et al.; OPT Pivotal 1 and OPT Pivotal 2 investigators. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br. J. Dermatol. 2015; 173(4): 949-61. doi: 10.1111/bjd.14018

Statistics

Views

Abstract - 25

PDF (Russian) - 0

Cited-By


Article Metrics

Metrics Loading ...

PlumX

Dimensions


Copyright (c) 2017 Natarova E.V., Rudneva N.S., Kuklina M.S., Chumakova Y.Y.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies